Characterization of the Canine MHC Class I DLA-88*50101 Peptide Binding Motif as a Prerequisite for Canine T Cell Immunotherapy

There are limitations in pre-clinical settings using mice as a basis for clinical development in humans. In cancer, similarities exist between humans and dogs; thus, the dog patient can be a link in the transition from laboratory research on mouse models to clinical trials in humans. Knowledge of the peptides presented on MHC molecules is fundamental for the development of highly specific T cell-based immunotherapies. This information is available for human MHC molecules but is absent for the canine MHC. In the present study, we characterized the binding motif of dog leukocyte antigen (DLA) class I allele DLA-88*50101, using human C1R and K562 transfected cells expressing the DLA-88*50101 heavy chain. MHC class I immunoaffinity-purification revealed 3720 DLA-88*50101 derived peptides, which enabled the determination of major anchor positions. The characterized binding motif of DLA-88*50101 was similar to HLA-A*02:01. Peptide binding analyses on HLA-A*02:01 and DLA-88*50101 via flow cytometry showed weak binding of DLA-88*50101 derived peptides to HLA-A*02:01, and vice versa. Our results present for the first time a detailed peptide binding motif of the canine MHC class I allelic product DLA-88*50101. These data support the goal of establishing dogs as a suitable animal model for the evaluation and development of T cell-based cancer immunotherapies, benefiting both dog and human patients.

[1]  G. Gao,et al.  Diversified Anchoring Features the Peptide Presentation of DLA-88*50801: First Structural Insight into Domestic Dog MHC Class I , 2016, The Journal of Immunology.

[2]  Keith Dobney,et al.  Genomic and archaeological evidence suggest a dual origin of domestic dogs , 2016, Science.

[3]  Morten Nielsen,et al.  Gapped sequence alignment using artificial neural networks: application to the MHC class I system , 2016, Bioinform..

[4]  H. Rammensee,et al.  Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy , 2015, Leukemia.

[5]  Hans-Georg Rammensee,et al.  HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL) , 2014, Proceedings of the National Academy of Sciences.

[6]  M. Maio,et al.  Peptide-based vaccines for cancer therapy , 2014, Human vaccines & immunotherapeutics.

[7]  S Walz,et al.  Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy , 2014, Leukemia.

[8]  S. Sawyer,et al.  Complete Mitochondrial Genomes of Ancient Canids Suggest a European Origin of Domestic Dogs , 2013, Science.

[9]  F. Dammacco,et al.  MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells. , 2013, Journal of the National Cancer Institute.

[10]  J. Steiner,et al.  Alleles of the major histocompatibility complex play a role in the pathogenesis of pancreatic acinar atrophy in dogs , 2013, Immunogenetics.

[11]  H. Rammensee,et al.  HLA ligandome tumor antigen discovery for personalized vaccine approach , 2013, Expert review of vaccines.

[12]  Stefano Comazzi,et al.  The dog as a possible animal model for human non‐Hodgkin lymphoma: a review , 2013, Hematological oncology.

[13]  K. Shokat,et al.  Complete Mitochondrial Genomes of Ancient Canids Suggest a European Origin of Domestic Dogs , 2013 .

[14]  S. Stevanović,et al.  Biochemical large-scale identification of MHC class I ligands. , 2013, Methods in molecular biology.

[15]  Jennifer C. Holmes,et al.  A cell-based MHC stabilization assay for the detection of peptide binding to the canine classical class I molecule, DLA-88. , 2012, Veterinary immunology and immunopathology.

[16]  J. Frelinger,et al.  Allelic diversity at the DLA-88 locus in Golden Retriever and Boxer breeds is limited. , 2012, Tissue antigens.

[17]  F. Gärtner,et al.  Canine tumors: a spontaneous animal model of human carcinogenesis. , 2012, Translational research : the journal of laboratory and clinical medicine.

[18]  J. Neefjes,et al.  Towards a systems understanding of MHC class I and MHC class II antigen presentation , 2011, Nature Reviews Immunology.

[19]  C. E. Alvarez,et al.  Dog models of naturally occurring cancer. , 2011, Trends in molecular medicine.

[20]  Jianping Ding,et al.  Structural modeling and biochemical studies reveal insights into the molecular basis of the recognition of β‐2‐microglobulin by antibody BBM.1 , 2009, Journal of molecular recognition : JMR.

[21]  M. Paoloni,et al.  Translation of new cancer treatments from pet dogs to humans , 2008, Nature Reviews Cancer.

[22]  William Stafford Noble,et al.  Semi-supervised learning for peptide identification from shotgun proteomics datasets , 2007, Nature Methods.

[23]  P. Jensen.  Recent advances in antigen processing and presentation , 2007, Nature Immunology.

[24]  J. Schellens,et al.  The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials , 2007, British Journal of Cancer.

[25]  R. Storb,et al.  An improved method for dog leukocyte antigen 88 typing and two new major histocompatibility complex class I alleles, DLA-88*01101 and DLA-88*01201. , 2007, Tissue antigens.

[26]  P. van Endert,et al.  Antigen processing and recognition. , 2007, Current opinion in immunology.

[27]  C. Hardt,et al.  Sequence-based typing reveals a novel DLA-88 allele, DLA-88*04501, in a beagle family. , 2005, Tissue antigens.

[28]  D. Wiley,et al.  Structure of the human class I histocompatibility antigen, HLA-A2. , 2005, Journal of immunology.

[29]  Hans-Georg Rammensee,et al.  The Tübingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy , 2004, Cancer Immunology, Immunotherapy.

[30]  O. Lund,et al.  novel sequence representations Reliable prediction of T-cell epitopes using neural networks with , 2003 .

[31]  Wolfgang M. Schleidt,et al.  Co-evolution of Humans and Canids An Alternative View of Dog Domestication: Homo Homini Lupus? , 2003 .

[32]  J. Neefjes,et al.  Antigen degradation or presentation by MHC class I molecules via classical and non-classical pathways. , 2002, Molecular immunology.

[33]  J A Gerlach,et al.  Nomenclature for factors of the dog major histocompatibility system (DLA), 2000: Second report of the ISAG DLA Nomenclature Committee. , 1999, Tissue antigens.

[34]  R. Storb,et al.  Dog class I gene DLA-88 histocompatibility typing by PCR-SSCP and sequencing. , 2000, Tissue antigens.

[35]  D. N. Perkins,et al.  Probability‐based protein identification by searching sequence databases using mass spectrometry data , 1999, Electrophoresis.

[36]  E. Ostrander,et al.  Polymorphism analysis of four canine MHC class I genes. , 2008, Tissue antigens.

[37]  D. Wartenberg,et al.  Environmental causes for sinonasal cancers in pet dogs, and their usefulness as sentinels of indoor cancer risk. , 1998, Journal of toxicology and environmental health. Part A.

[38]  J. Reif,et al.  Cancer of the nasal cavity and paranasal sinuses and exposure to environmental tobacco smoke in pet dogs. , 1998, American journal of epidemiology.

[39]  R. Storb,et al.  Molecular analysis of six dog leukocyte antigen class I sequences including three complete genes, two truncated genes and one full-length processed gene. , 1997, Tissue antigens.

[40]  F. Momburg,et al.  Residues in TAP2 peptide transporters controlling substrate specificity. , 1996, Journal of immunology.

[41]  A. Dutra,et al.  Gene localization and syntenic mapping by FISH in the dog. , 1996, Cytogenetics and cell genetics.

[42]  H. Rammensee,et al.  HLA-A2 subtypes are functionally distinct in peptide binding and presentation , 1995, The Journal of experimental medicine.

[43]  D. Geraghty,et al.  Structure and expression of a divergent canine class I gene. , 1995, Journal of immunology.

[44]  R. Obst,et al.  TAP polymorphism does not influence transport of peptide variants in mice and humans , 1995, European journal of immunology.

[45]  R. Moots,et al.  Significance of the six peptide-binding pockets of HLA-A2.1 in influenza A matrix peptide-specific cytotoxic T-lymphocyte reactivity. , 1994, Human immunology.

[46]  K. Hogan,et al.  Both major and minor peptide-binding pockets in HLA-A2 influence the presentation of influenza virus matrix peptide to cytotoxic T lymphocytes. , 1994, Molecular immunology.

[47]  V. Gnau,et al.  Allele-specific peptide ligand motifs of HLA-C molecules. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[48]  S. Stevanović,et al.  Multiple sequence analysis: pool sequencing of synthetic and natural peptide libraries. , 1993, Analytical biochemistry.

[49]  J. Frelinger,et al.  Roles of the six peptide-binding pockets of the HLA-A2 molecule in allorecognition by human cytotoxic T-cell clones. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[50]  P. Parham,et al.  The HLA-A,B "negative" mutant cell line C1R expresses a novel HLA-B35 allele, which also has a point mutation in the translation initiation codon. , 1992, Journal of immunology.

[51]  B. Walker,et al.  An optimal viral peptide recognized by CD8+ T cells binds very tightly to the restricting class I major histocompatibility complex protein on intact cells but not to the purified class I protein. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[52]  H. Rammensee,et al.  Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules , 1991, Nature.

[53]  Hans-Georg Rammensee,et al.  Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells , 1990, Nature.

[54]  T. Elliott,et al.  Assembly of MHC class I molecules analyzed in vitro , 1990, Cell.

[55]  H. Ljunggren,et al.  Association of class I major histocompatibility heavy and light chains induced by viral peptides , 1989, Nature.

[56]  P. Cresswell,et al.  NK susceptibility varies inversely with target cell class I HLA antigen expression. , 1987, Journal of immunology.

[57]  P. Edwards,et al.  A human‐human hybridoma system based on a fast‐growing mutant of the ARH‐77 plasma cell leukemia‐derived line , 1982, European journal of immunology.

[58]  R. Tarone,et al.  Bladder cancer in pet dogs: a sentinel for environmental cancer? , 1981, American journal of epidemiology.

[59]  C. Lozzio,et al.  A Multipotential Leukemia Cell Line (K-562) of Human Origin 1 , 1981, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[60]  P. Parham,et al.  Structure of HLA antigens: amino-acid and carbohydrate compositions and NH2-terminal sequences of four antigen preparations. , 1976, Proceedings of the National Academy of Sciences of the United States of America.